Stay at the forefront of biopharmaceutical innovation. Subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Related to this article

November 4th, 2026

The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic

Boehringer Ingelheim licenses six preclinical ADC and T-cell engager programs from Sino Biopharmaceutical in a deal worth up to $7 billion, Spyre Therapeutics drops anti-TL1A antibody SPY072 in rheumatic diseases after phase 2 misses and turns to hidradenitis suppurativa, and Biora Therapeutics gets ethics approval for a first-in-human trial of its BioJet oral adalimumab capsule.

November 4th, 2026

Q&A: What AI Reveals That Scientists Could Not See Before

Matt Trupo, Richard Jaenisch, and Brian Drapeau explore how AI advances biological insights, drug-target discovery, and supply chains.

November 4th, 2026

The Promise of Microgravity for R&D and Manufacturing

As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.

Hand inserts a molecule into DNA. | Image credit: © natali_mis - © natali_mis - stock.adobe.com

November 4th, 2026

Aldevron, IDT Launch Base and Prime Editing mRNAs for Gene Editing

Aldevron and IDT added PE Ultra prime editor mRNA and 6 ABE8e base editor mRNAs to help researchers edit DNA without double-strand breaks.

Close-up of an older person’s hands with several finger joints highlighted in red, against a white background. | Image Credit: © doucefleur - stock.adobe.com

November 4th, 2026

Spyre’s Anti-TL1A Antibody SPY072 Misses in Psoriatic Arthritis and Axial Spondyloarthritis, Shifts Focus to Hidradenitis Suppurativa

The half-life-extended antibody failed its primary endpoints in two Phase 2 SKYWAY sub-studies, so Spyre is dropping it in rheumatic diseases and moving it into a combination trial in hidradenitis suppurativa.

white pill capsule isolated on white background | Image credit: © F16-ISO100 - © F16-ISO100 - stock.adobe.com

November 4th, 2026

Biora Wins Ethics Approval for First Human Trial of BioJet Capsule

Biora will test oral adalimumab via its BioJet capsule vs injection in healthy volunteers, with dosing from December 2026 and data in early 2027.

3D illustration of several small, round gray-green immune cells clustered around and on top of a large purple cancer cell with long branching projections, against a dark red background. | Image Credit: © PRB ARTS - stock.adobe.com

November 4th, 2026

Boehringer Ingelheim Licenses Six Preclinical ADC and T-Cell Engager Programs From SBP Group in Deal Worth Up to $7 Billion

Boehringer Ingelheim will pay Sino Biopharmaceutical $358 million upfront and near-term for options on six biologic oncology programs, deepening a partnership that began in 2024.

Exterior of the US Treasury Department building in Washington, DC, with columns along its facade. | Image Credit: © Zack Frank - stock.adobe.com

November 4th, 2026

Policy Leaders Urge Treasury to Narrow Biotech Outbound Investment Rule

A former CIA officer, Pacific Research Institute economists, and industry groups say Treasury's proposed COINS Act biotechnology restrictions are too broad, while the National Security Commission on Emerging Biotechnology backs the move. Comments are due December 7, 2026.

Elements of Biopharmaceutical Production Series

Related to this article

Trending on BioPharm International

Policy Leaders Urge Treasury to Narrow Biotech Outbound Investment Rule

Spyre’s Anti-TL1A Antibody SPY072 Misses in Psoriatic Arthritis and Axial Spondyloarthritis, Shifts Focus to Hidradenitis Suppurativa

Shilpa CDMO Commits $50 Million to Scale Peptide Capacity in India

Boehringer Ingelheim Licenses Six Preclinical ADC and T-Cell Engager Programs From SBP Group in Deal Worth Up to $7 Billion

Biora Wins Ethics Approval for First Human Trial of BioJet Capsule